Infectious Disease Diagnostics Market: Roche and Abbott Leading the Way

The infectious disease diagnostics market is valued at an estimated USD 21.4 billion in 2023 and is projected to reach USD 31.5 billion by 2028 at a CAGR of 8.0% during the forecast period. Market growth is largely driven by the rising prevalence of infectious diseases and the increasing funding for R&D in disease diagnostics. The rising incidence of infectious diseases worldwide creates a substantial demand for effective diagnostic tools. As the global healthcare landscape grapples with the challenges posed by infectious agents, there is a heightened emphasis on developing advanced diagnostic technologies to enable timely and accurate detection.

Download an Illustrative overview:

Browse in-depth TOC on “Infectious Disease Diagnostics Market”

172 — Tables
53 — Figures
309 — Pages

Key Market Players of Infectious Disease Diagnostics Industry:

The major players operating in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche Ltd. (Switzerland) held a leading position in the infectious disease diagnostics market. The company has maintained this position in the market through its strong distribution networks across North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Roche has a strong direct and indirect distribution network globally, which helps insulate its business from demand fluctuations in various geographies. The company adopts inorganic growth strategies to increase its dominance in this market. The company focuses on strategies, such as partnerships and acquisitions, to garner a larger market share. the company launched cobas 5800 molecular laboratory instruments used for infectious disease diagnostics.

Abbott (US) held a significant market share in the infectious disease diagnostics market. Its dominant position in this market can be credited to the robust global sales and distribution network, allowing effective product marketing across diverse countries. Additionally, Abbott has heightened its emphasis on research and development endeavors. The company’s substantial investments in R&D, aimed at refining its portfolio and optimizing capital allocation strategies, contribute to its prospective growth and sustained competitiveness in the Diagnostics segment.In addition, Abbott’s strategies, which involve product launches and regulatory approvals, aim to further strengthen its position in the infectious disease diagnostics market. For instance, in March 2021, the company received Emergency Use Authorization (EUA) from the FDA for a laboratory PCR assay, Alinity m Resp-4-Plex molecular assay, that detects and differentiates between SARS-COV-2, flu A, flu B, and RSV in one test.

bioMérieux (France) accounted for the third largest share of the infectious disease diagnostics market. The company has successfully positioned itself as a strong player in the infectious disease diagnostics market. The firm focuses on developing innovative products for infectious disease indications. the company received a CE mark for its VIDAS tests for Chikungunya virus diagnosis.

North America is the largest regional market for infectious disease diagnostics market.

The market for infectious disease diagnostics has been divided into five key geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the predominant portion of the infectious disease diagnostics market. The infectious disease diagnostics market in North America is well-established, with the US being a major market in this region. This dominance can be attributed to various factors, including advanced healthcare infrastructure, a high prevalence of infectious diseases, and significant investments in diagnostic technologies.

Request Sample Pages:

The break-up of the profile of primary participants in the infectious disease diagnostics market:

  • By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3–30%
  • By Designation: C-level — 27%, D-level — 18%, and Others — 55%
  • By Region: North America — 51%, Europe — 21%, Asia Pacific — 18%, Latin America — 6%, and Middle East & Africa- 4%

Infectious Disease Diagnostics Market Recent Developments:

  • Thermo Fisher Scientific Inc. (US) launched its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit.
  • Roche launched Elecsys HCV Duo, an immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
  • Siemens Healthineers released its CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Test.
  • Roche completed a purchase agreement with TIB Molbiol (Germany) to expand the PCR-test portfolio in the fight against new infectious diseases.
  • Cepheid collaborated with Sherlock Biosciences (US). This collaboration between the two companies aimed to explore the development of new cutting-edge molecular diagnostic tests for infectious diseases leveraging CRISPR technology.

Infectious Disease Diagnostics Market — Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising prevalence of infectious diseases, Rising focus on R&D and funding in infectious disease diagnostic products, Growing awareness for early disease diagnosis in emerging economies, Adoption of new and advanced technologies for infectious disease diagnosis, Shift in focus from centralized laboratories to decentralized PoC testing centers), opportunities (Increased growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (Changing regulatory landscape, Operational barriers and shortage of skilled laboratory technicians) influencing the growth of the infectious disease diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the infectious disease diagnostics market.
  • Market Development: Comprehensive information about lucrative markets — the report analyses the infectious disease diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the infectious disease diagnostics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), and Thermo Fisher Scientific Inc. (US), among others in the infectious disease diagnostics market strategies.

Get 10% Free Customization on this Report: